Compare EXAS & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXAS | LII |
|---|---|---|
| Founded | 1995 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 17.7B |
| IPO Year | N/A | 1999 |
| Metric | EXAS | LII |
|---|---|---|
| Price | $102.34 | $511.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 13 |
| Target Price | $81.27 | ★ $600.17 |
| AVG Volume (30 Days) | ★ 2.3M | 325.1K |
| Earning Date | 02-18-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 0.99% |
| EPS Growth | N/A | ★ 12.46 |
| EPS | N/A | ★ 23.67 |
| Revenue | $3,082,033,000.00 | ★ $5,345,300,000.00 |
| Revenue This Year | $19.40 | N/A |
| Revenue Next Year | $13.51 | $6.38 |
| P/E Ratio | ★ N/A | $22.22 |
| Revenue Growth | ★ 14.47 | 3.77 |
| 52 Week Low | $38.81 | $443.19 |
| 52 Week High | $102.66 | $689.44 |
| Indicator | EXAS | LII |
|---|---|---|
| Relative Strength Index (RSI) | 83.39 | 49.97 |
| Support Level | $101.51 | $518.66 |
| Resistance Level | $102.56 | $531.86 |
| Average True Range (ATR) | 0.32 | 14.14 |
| MACD | -0.61 | 0.63 |
| Stochastic Oscillator | 81.91 | 44.95 |
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.